Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HBC.OL
- Price
- 2.10
- Stock movement up
- +- (%)
- Company name
- Hofseth Biocare ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 829.66M
- Ent value
- 1.05B
- Price/Sales
- 3.74
- Price/Book
- 6.03
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -1.18%
- 1 year return
- -1.41%
- 3 year return
- -23.44%
- 5 year return
- -22.59%
- 10 year return
- -2.56%
Last updated: 2025-04-15
DIVIDENDS
HBC.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.74 |
| Price to Book | 6.03 |
| EV to Sales | 4.74 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 395.08M |
| EPS (TTM) | -0.31 |
| FCF per share (TTM) | -0.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 221.87M |
| Gross profit (TTM) | 63.60M |
| Operating income (TTM) | -120.44M |
| Net income (TTM) | -121.18M |
| EPS (TTM) | -0.31 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 28.67% |
| Operating margin (TTM) | -54.28% |
| Profit margin (TTM) | -54.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 25.30M |
| Net receivables | 27.00M |
| Total current assets | 135.82M |
| Goodwill | 0.00 |
| Intangible assets | 45.74M |
| Property, plant and equipment | 152.66M |
| Total assets | 385.53M |
| Accounts payable | 70.46M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 155.52M |
| Total liabilities | 247.98M |
| Shareholder's equity | 137.55M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.00M |
| Capital expenditures (TTM) | 17.84M |
| Free cash flow (TTM) | -33.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -88.10% |
| Return on Assets | -31.43% |
| Return on Invested Capital | -88.10% |
| Cash Return on Invested Capital | -24.60% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.10 |
| Daily high | 2.10 |
| Daily low | 1.91 |
| Daily Volume | 11K |
| All-time high | 10.91 |
| 1y analyst estimate | - |
| Beta | 0.34 |
| EPS (TTM) | -0.31 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 9 May 2025 |
Downside potential
Loading...
Downside potential data
| HBC.OL | S&P500 | |
| Current price drop from All-time high | -80.76% | -12.04% |
| Highest price drop | -89.09% | -56.47% |
| Date of highest drop | 3 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -49.24% | -11.07% |
| Avg time to new high | 184 days | 12 days |
| Max time to new high | 1353 days | 1805 days |
COMPANY DETAILS
Marketcap
829.66M
Marketcap category
Small-cap
Description
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Employees
69
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2024, and HBC has today published the Annual Report and Sustainability Report for 2024. Please find the ...
April 11, 2025
Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in...
March 10, 2025
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...
February 21, 2025
HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo® ...
February 14, 2025
Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis pla...
December 5, 2024
HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
November 8, 2024
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral...
October 8, 2024
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72...
August 23, 2024
Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically l...
August 14, 2024
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate ...
July 2, 2024
Next page